Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug pirtobrutinib tested for Long-Term safety in blood cancers

NCT ID NCT07218341

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 6 times

Summary

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They will take pirtobrutinib by mouth every 4 weeks for up to 5 years, and researchers will track any serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pirtobrutinib
What this could lead to
If successful, this study could confirm that pirtobrutinib is safe for long-term use in people with CLL or SLL, supporting its continued use as a treatment option.
What could go wrong
This is an open-label safety study, not designed to prove effectiveness. Side effects like grade 3 or higher adverse events may occur, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020 Exclusion Criteria: * This is not applicable to this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia Lymphoma, small lymphocytic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    50 sites in 17 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta

    NOT_YET_RECRUITING

    Roeselare, 8800, Belgium

  • Affiliated Cancer Hospital of Xinjiang Medical University

    NOT_YET_RECRUITING

    Ürümqi, 830000, China

  • Arizona Oncology Associates, P.C. - HOPE

    NOT_YET_RECRUITING

    Tucson, Arizona, 85711, United States

  • Azienda Ospedaliera S. Maria Di Terni

    NOT_YET_RECRUITING

    Terni, 05100, Italy

  • Azienda Ospedaliera Universitaria Careggi

    NOT_YET_RECRUITING

    Florence, 50134, Italy

  • Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia

    NOT_YET_RECRUITING

    Perugia, 06129, Italy

  • Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo

    NOT_YET_RECRUITING

    Alessandria, 15121, Italy

  • Beaumont Hospital

    NOT_YET_RECRUITING

    Dublin, DUBLIN 9, Ireland

  • Cancer Specialists, LLC

    RECRUITING

    Jacksonville, Florida, 32256, United States

  • Castle Hill Hospital

    NOT_YET_RECRUITING

    Hull, HU16 5JQ, United Kingdom

  • Cayuga Cancer Center

    NOT_YET_RECRUITING

    Ithaca, New York, 14850, United States

  • Centre Henri Becquerel

    NOT_YET_RECRUITING

    Rouen, 76038, France

  • Debreceni Egyetem

    NOT_YET_RECRUITING

    Debrecen, 4032, Hungary

  • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet

    NOT_YET_RECRUITING

    Budapest, 1097, Hungary

  • Fakultni nemocnice Hradec Kralove

    NOT_YET_RECRUITING

    Hradec Králové, 500 05, Czechia

  • Fondazione IRCCS San Gerardo dei Tintori

    NOT_YET_RECRUITING

    Monza, 20900, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    NOT_YET_RECRUITING

    Rome, 00138, Italy

  • Fudan University Shanghai Cancer Center

    NOT_YET_RECRUITING

    Shanghai, 200032, China

  • Gansu Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Lanzhou, 730050, China

  • GenesisCare

    NOT_YET_RECRUITING

    Newmarket, CB8 7XN, United Kingdom

  • Hematology Hospital of the Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, 300020, China

  • Henan Cancer Hospital

    NOT_YET_RECRUITING

    Zhengzhou, 450003, China

  • Hospital Universitario Marques De Valdecilla

    NOT_YET_RECRUITING

    Santander, 39008, Spain

  • Hospital Universitario Virgen Del Rocio

    NOT_YET_RECRUITING

    Seville, 41010, Spain

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, 410013, China

  • LKH - Universitätsklinikum der PMU Salzburg

    NOT_YET_RECRUITING

    Salzburg, 5020, Austria

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    RECRUITING

    New York, New York, 10065-6007, United States

  • Minnesota Oncology Hematology, P.A.

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Mitchell Cancer Institute

    RECRUITING

    Mobile, Alabama, 36693, United States

  • Nanfang Hospital of Southern Medical University

    NOT_YET_RECRUITING

    Guangzhou, 510515, China

  • Oncology Hematology Care Inc

    NOT_YET_RECRUITING

    Cincinnati, Ohio, 45211, United States

  • Pratia Onkologia Katowice

    NOT_YET_RECRUITING

    Katowice, 40-519, Poland

  • Presidio Ospedaliero Papardo

    NOT_YET_RECRUITING

    Messina, 98158, Italy

  • Princess Margaret Cancer Centre - University Health Network

    NOT_YET_RECRUITING

    Toronto, M5G 2M9, Canada

  • St James's University Hospital

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • St. James's Hospital

    NOT_YET_RECRUITING

    Dublin, D08 NHY1, Ireland

  • Sun Yat-sen University Cancer Center

    NOT_YET_RECRUITING

    Guangdong, 510060, China

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza

    NOT_YET_RECRUITING

    Brzozów, 36-200, Poland

  • Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy

    NOT_YET_RECRUITING

    Bydgoszcz, 85-168, Poland

  • Taizhou Hospital of Zhejiang Province

    NOT_YET_RECRUITING

    Taizhou, 317000, China

  • Tel Aviv Sourasky Medical Center

    NOT_YET_RECRUITING

    Tel Aviv, 6423906, Israel

  • Texas Oncology - Paris

    NOT_YET_RECRUITING

    Fort Worth, Texas, 76104, United States

  • The Affiliated Hospital of Xuzhou Medical College

    NOT_YET_RECRUITING

    Xuzhou, 221000, China

  • The Alfred Hospital

    NOT_YET_RECRUITING

    Melbourne, 3004, Australia

  • The First Affiliated Hospital of Nanchang University

    NOT_YET_RECRUITING

    Nanchang, 330006, China

  • Tianjin Medical University Cancer Institute & Hospital

    NOT_YET_RECRUITING

    Tianjin, 300060, China

  • Tokai University Hospital

    RECRUITING

    Isehara, 259-1193, Japan

  • US Oncology - Texas Oncology

    NOT_YET_RECRUITING

    Kyle, Texas, 78640, United States

  • University Hospital Center Zagreb

    NOT_YET_RECRUITING

    Zagreb, 10000, Croatia

  • Xuanwu Hospital Capital Medical University

    NOT_YET_RECRUITING

    Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.